Liquid Metformin 100 mg/mL
DrugA single oral dose of a liquid metformin formulation at a concentration of 100 mg/mL will be administered under fasting conditions in one treatment period of the crossover.
NCT Number: NCT07300033
This is an open-label, randomized, two-treatment, two-period crossover study evaluating the bioequivalence of liquid metformin formulations at 100 mg/mL and 250 mg/mL compared with immediate-release metformin tablets in healthy adult subjects. Each participant will receive both treatments in randomized sequence with an adequate washout interval between periods. Serial blood samples will be collected to assess metformin pharmacokinetics, and safety will be monitored throughout the study.
Trial opening soon.
Get Notified18 year–55 year
All sexes
Interventional
Phase 1
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Body mass index (BMI) between 18.0 and 30.0 kg/m², inclusive.
Medically healthy based on medical history, physical examination, vital signs, clinical laboratory tests, and 12-lead ECG, in the opinion of the investigator.
Non-smoker or light smoker (10 or fewer cigarettes per day or equivalent) willing to abstain from smoking during confinement periods.
Able to understand and provide written informed consent prior to participation in the study.
Willing and able to comply with all study requirements, including fasting requirements and pharmacokinetic blood sampling.
Females of childbearing potential must use an acceptable method of contraception as determined by the investigator.
Exclusion criteria
History or presence of any clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, neurologic, or psychiatric disorder that, in the opinion of the investigator, could interfere with study participation or interpretation of results.
Estimated glomerular filtration rate (eGFR) less than 90 mL/min/1.73 m², or any clinically significant abnormal clinical laboratory findings.
History of lactic acidosis.
Use of prescription or over-the-counter medications, herbal supplements, or dietary supplements within 14 days before the first study dose, unless approved by the investigator.
Positive test for hepatitis B surface antigen, hepatitis C antibody, or HIV.
Positive urine drug screen or positive alcohol breath test at screening or admission.
Participation in another clinical trial or receipt of an investigational product within 30 days or 5 half-lives (whichever is longer) before the first study dose.
Donation of 450 mL or more of blood, or significant blood loss, within 8 weeks before first study dose.
Pregnant or breastfeeding females.
Women of childbearing potential not using acceptable contraception.
Any condition or situation that, in the opinion of the investigator, would make the participant unsuitable for the study.
A single oral dose of a liquid metformin formulation at a concentration of 100 mg/mL will be administered under fasting conditions in one treatment period of the crossover.
A single oral dose of a liquid metformin formulation at a concentration of 250 mg/mL will be administered under fasting conditions in one treatment period of the crossover.
A single oral dose of standard immediate-release metformin tablet(s) will be administered under fasting conditions in one treatment period of the crossover.
Time frame: Up to approximately 24 to 36 hours postdose in each treatment period
Time frame: Up to approximately 24 to 36 hours postdose in each treatment period
Contact information is provided by the study sponsor or research team.
Aspargo Labs, Inc
Industry
Bioequivalence of Liquid Metformin (100 mg/mL and 250 mg/mL) and Immediate-Release Metformin Tablets: A Randomized, Crossover Study in Adult Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06690294
Behavior, Behavior, Animal
Phoenix, Arizona, United States
View Trial DetailsNCT07566468
ADHD, Anxiety Disorders
Bethesda, Maryland, United States
View Trial DetailsNCT07637656
Healthy Volunteer
Phoenix, Arizona, United States
View Trial DetailsNCT07728175
APOE-4 Positive, Disease Attributes
Columbia, Missouri, United States
View Trial Details